Samay specializes in remote respiratory health management. It develops AI-enabled wearable devices that monitor pulmonary volumes, trapped air, heart rates, breathing sounds, and lung temperature. This enables users to analyze their respiratory data and helps prevent respiratory diseases.
APrevent Medical
Non Equity Assistance in 2024
APrevent Medical Inc. is a medical device company founded in 2014 and headquartered in Taipei, Taiwan, with an additional office in Austria. The company specializes in developing therapeutic medical devices aimed at enhancing the quality of life for patients suffering from speech disorders. APrevent Medical focuses on innovative solutions, including a long-term implant system and a speech conversion platform, designed to provide minimally invasive treatments and support for voice and communication issues. By integrating advanced technologies, the company aims to offer effective interventions that enable patients to improve their speech capabilities and overall communication.
INIA Biosciences
Non Equity Assistance in 2024
INIA Biosciences is a developer of innovative medical devices that leverage sound wave technology to create non-invasive, home-administered systems for managing chronic inflammatory diseases. The company focuses on a closed-loop monitoring system designed to treat and prevent organ failure by integrating biomarker monitoring with an ultrasound stimulator. This approach aims to reduce inflammation linked to transplant rejection rates and minimize reliance on immunosuppressant drugs. By providing novel diagnostic sensing capabilities, INIA Biosciences enables physicians to better manage chronic diseases and improve patient outcomes.
Nanotis
Non Equity Assistance in 2024
Nanotis Corporation, founded in 2016 and based in Tokyo, Japan, specializes in the development of instant diagnostic devices aimed at addressing challenges in infectious disease testing, particularly for influenza. The company manufactures microchip-based devices that allow users to quickly and accurately diagnose illnesses. By providing early diagnosis solutions, Nanotis supports medical professionals in practical healthcare settings, thereby enhancing the efficiency of healthcare delivery and improving patient outcomes.
Samay
Non Equity Assistance in 2024
Samay specializes in remote respiratory health management. It develops AI-enabled wearable devices that monitor pulmonary volumes, trapped air, heart rates, breathing sounds, and lung temperature. This enables users to analyze their respiratory data and helps prevent respiratory diseases.
FemTherapeutics
Non Equity Assistance in 2024
FemTherapeutics is a Montreal-based medical device company dedicated to personalizing therapeutics in women’s health. It uses artificial intelligence and patient data to design customized gynecological prosthetics, initially focusing on improving the management of Pelvic Floor Disorders.
Acorai
Non Equity Assistance in 2024
Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.
Flow Medical
Non Equity Assistance in 2024
Flow Medical develops a thrombolysis catheter designed to treat pulmonary embolism. Its catheter improves clot visualization, delivers medication directly to the blockage, and monitors treatment progress in real-time, enabling personalized therapy.
NanoBioFAB
Non Equity Assistance in 2024
NanoBioFAB is a company based in Frederick, Maryland, specializing in the development of wearable, smart healthcare and medical devices utilizing nanotechnology. Founded in 2015, the company produces innovative products such as iNose, a device that allows individuals to detect, track, and monitor their body’s skin vapor-print. This device connects wirelessly to mobile phones, enabling users to track their fat burning rate, assess the effectiveness of their exercise routines, and observe the long-term effects of their dietary choices on metabolic rates. Additionally, NanoBioFAB offers nanoprinting technology and artificial intelligence sensors aimed at enhancing telemedicine and personalized healthcare solutions. The company is dedicated to making advanced healthcare accessible and affordable for both people and pets.
Promedius
Non Equity Assistance in 2024
Founded in 2019, Promedius is a company dedicated to transforming the approach to aging through innovative technologies aimed at the early detection and management of musculoskeletal and metabolic diseases, particularly osteoporosis. Promedius has developed PROS® CXR:OSTEO, a pioneering screening solution that utilizes chest X-ray images combined with artificial intelligence to identify individuals at risk for osteoporosis. This technology is designed to prevent severe fractures among the elderly population, facilitating timely intervention and enhancing the overall quality of life. By harnessing AI in medical imaging, Promedius aims to support healthcare professionals in their efforts to improve patient outcomes and extend healthy lifespans.
FibriCheck
Non Equity Assistance in 2024
FibriCheck is a medically certified application designed for the screening and monitoring of irregular heart rhythms, including atrial fibrillation. Functioning as a software-only solution, it allows users to measure their cardiac rhythm simply by placing a finger on their smartphone camera, making it accessible for use anytime and anywhere. The application automatically shares the collected data with medical professionals, facilitating quicker diagnoses and the development of appropriate treatment plans. Additionally, FibriCheck employs an artificial intelligence platform that is device-agnostic, enabling it to leverage everyday smartphones and wearables. This innovative approach aims to enhance cardiovascular care by accurately detecting and tracking heart rhythm issues, while also helping individuals manage conditions such as high blood pressure and heart failure through user-friendly tools and customizable health plans.
Ortho-tag
Non Equity Assistance in 2024
Ortho-tag is a developer of innovative in-vivo platforms that facilitate the connection between digital health applications and implanted biosensors within the human body. The company's technologies focus on enhancing wireless communication with medical devices through proprietary transcutaneous volume conduction. This enables real-time data exchange, in-vivo storage, and the integration of nanodiagnostic and therapeutic functions in smart medical implants. By providing a comprehensive system for wireless communication and data management, Ortho-tag supports medical device developers in advancing the capabilities of healthcare technology.
AccurKardia
Non Equity Assistance in 2024
AccurKardia is an innovative company specializing in ECG-led diagnostics software. It transforms ECG data into a powerful tool to improve patient outcomes globally, with initial applications in cardiology. The company offers AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) for automated, near real-time ECG interpretation. Its AI-driven hyperkalemia detection solution, AK+ Guard™, received FDA Breakthrough Device Designation.
Invicta Medical
Non Equity Assistance in 2024
Invicta Medical develops innovative medical technologies for advanced sleep apnea treatments. Founded in 2013, the company is headquartered in Santa Clara, California.
Qritive
Non Equity Assistance in 2024
Qritive is a technology company that offers an artificial intelligence-powered diagnostic platform aimed at enhancing the accuracy and efficiency of cancer diagnoses. By utilizing advanced AI and natural language processing, Qritive's solution enables medical professionals to analyze microscopy images alongside patients' medical histories. This innovative approach allows hospitals to streamline their diagnostic processes, ultimately reducing costs and improving patient outcomes. With the rising incidence of cancer, Qritive addresses a critical need in the healthcare sector, equipping doctors with modern tools to aid in timely and precise cancer detection.
iCE Neurosystems
Non Equity Assistance in 2024
iCE Neurosystems is a developer of an advanced neuromonitoring platform aimed at enhancing the diagnosis and treatment of brain injuries. The company combines innovative devices, cutting-edge software, and big-data analytics to deliver real-time insights into brain health. This integration enables healthcare professionals to receive early warnings and guide treatment for patients suffering from brain injuries, particularly in critical care settings. By providing revolutionary insights, iCE Neurosystems enhances the ability of doctors and nurses to diagnose and prevent brain injuries more effectively.
VinBrain
Non Equity Assistance in 2024
VinBrain is a healthcare technology company that specializes in artificial intelligence applications within the medical field, particularly in medical imaging and diagnostics. The company offers DrAidTM Teleradiology, a remote medical imaging solution that facilitates the connection of resources and expertise between hospitals, ensuring patients receive quality diagnostic imaging services anytime and anywhere. VinBrain's platform enhances patient outcomes by identifying and distinguishing various types of cancerous cells and tissues, analyzing medical histories to pinpoint potential risk factors, and automatically generating reports based on healthcare data. Utilizing computer vision and generative AI, the company streamlines radiologists' workflows, providing healthcare providers with valuable insights to improve diagnosis, treatment, and overall patient care, while also enhancing operational efficiency.
Prevencio
Non Equity Assistance in 2024
Prevencio is a biotechnology company focused on developing innovative multi-proteomic biomarkers aimed at transforming blood tests for cardiovascular disease. Utilizing artificial intelligence, the company's biomarkers analyze established clinical data sets to create novel, multi-protein tests that are algorithmically scored. These tests enable clinicians to evaluate the effects of medications before and after administration, specifically concerning a composite risk of heart attack, stroke, and cardiac death. By leveraging advanced technology in biomarker development, Prevencio seeks to enhance the accuracy and effectiveness of cardiovascular diagnostics.
Craif
Non Equity Assistance in 2024
Craif develops innovative devices for early cancer detection using urine tests. Founded in 2018, the company aims to improve cancer survival rates by enabling painless, accurate, and regular diagnosis through its MicroRNA technology.
NIRAMAI Health Analytix
Non Equity Assistance in 2024
NIRAMAI Health Analytix Private Limited is a Bengaluru-based company that specializes in cancer screening through its innovative software, Thermalytix, which leverages machine intelligence to analyze thermography images. Founded in 2016, the company offers a range of hardware-software solutions tailored for various users, including a compact screening device for specialty hospitals, a handheld device for independent medical practitioners, and a portable solution designed for large-scale screenings. NIRAMAI's technology enables early detection of breast cancer, identifying tumors significantly smaller than those detectable by traditional methods. Their approach is non-contact, painless, and free of radiation, making it a low-cost and accessible option for women of all age groups to undergo frequent screenings without adverse effects. By facilitating early diagnosis, NIRAMAI aims to improve survival rates and enhance the quality of cancer care.
Cyted Health
Non Equity Assistance in 2024
Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.
DiaMonTech
Non Equity Assistance in 2024
Founded in 2015, DiaMonTech specializes in developing non-invasive medical diagnostic devices. Its proprietary photo-thermal detection technology enables accurate glucose level measurements without finger pricking or blood samples.
Astek Diagnostics
Non Equity Assistance in 2024
Astek Diagnostics is a healthcare company that develops precision diagnostic technology aimed at improving the diagnosis and treatment of bacterial infections. The company has created a platform that assists physicians in prescribing the correct antibiotics for patients suffering from bacterial sepsis within one hour. Utilizing a single-use cartridge, Astek Diagnostics' device identifies bacterial infections in urine by measuring the oxygen consumption of bacterial species, significantly reducing the turnaround time for results. This innovative approach not only facilitates timely treatment but also helps combat antibiotic resistance through effective susceptibility testing.
Neurava is a healthcare company focused on improving the lives of epilepsy patients through the development of non-invasive wearable diagnostic devices. These devices monitor critical biological signals associated with epilepsy and the risk of sudden unexpected death in epilepsy (SUDEP), offering a reliable solution for both patients and their caregivers. By providing accurate and timely alerts, especially during nighttime, Neurava's technology empowers caregivers to respond quickly and take preventive actions, thereby enhancing patient safety and peace of mind. The company's commitment to advancing medical device manufacturing and health diagnostics highlights its role in addressing the challenges faced by those with uncontrolled epilepsy.
StrokeDx is a company that specializes in the development of innovative and portable diagnostic devices aimed at revolutionizing stroke care. Through the use of advanced microsensors and artificial intelligence, StrokeDx's products can quickly detect blood presence in the brain, generating predictive images of stroke locations after scanning. This technology significantly reduces the time to treatment for stroke patients and is designed to be more cost-effective than traditional diagnostic methods. The company employs a dedicated software engineering team focused on creating novel algorithms that enhance the diagnostic accuracy and imaging capabilities of its devices, ultimately improving the triage and diagnosis process for healthcare providers.
IFPx is a company focused on developing innovative monitoring technology for patients with chronic illnesses, beginning with heart failure. The company has created a patient monitoring device that directly analyzes fluid buildup, which is crucial for managing such conditions. By utilizing interstitial fluid pressure sensors, IFPx aims to enhance the monitoring capabilities available to healthcare professionals, thereby improving patient outcomes in heart failure management. The company's technology represents a significant advancement in the approach to chronic illness treatment, emphasizing the importance of real-time data in patient care.
Biotome
Non Equity Assistance in 2023
Biotome is a biotechnology research firm focused on developing advanced antibody diagnostic tests. The company specializes in identifying markers that indicate a high risk of stomach cancer, aiming to provide more precise and detailed disease information compared to current screening methods. By leveraging next-generation technology and precision immunology, Biotome's tests are designed to enhance the ability of medical professionals to treat patients effectively.
StrokeDx
Non Equity Assistance in 2023
StrokeDx is a company that specializes in the development of innovative and portable diagnostic devices aimed at revolutionizing stroke care. Through the use of advanced microsensors and artificial intelligence, StrokeDx's products can quickly detect blood presence in the brain, generating predictive images of stroke locations after scanning. This technology significantly reduces the time to treatment for stroke patients and is designed to be more cost-effective than traditional diagnostic methods. The company employs a dedicated software engineering team focused on creating novel algorithms that enhance the diagnostic accuracy and imaging capabilities of its devices, ultimately improving the triage and diagnosis process for healthcare providers.
AMI
Non Equity Assistance in 2023
AMI Co., Ltd is a Japanese company based in Minamata-shi, established in 2015, that specializes in the manufacturing of medical equipment, primarily stethoscopes. In addition to producing medical devices, AMI is involved in healthcare consulting, offering services such as hospital management and clinical research. The company is also focused on developing telehealth solutions, including a telemedicine system that enhances remote medical consultations. Among its innovations is a video chat platform designed for remote auscultation, which allows for the separate transmission of heart sounds as both audible and visible data, thereby improving patient access to medical services through telemedicine initiatives.
SafeGuard Surgical
Non Equity Assistance in 2023
SafeGuard Surgical is a medical device company focused on improving surgical outcomes and patient safety. It develops innovative, resorbable products designed to enhance colonic anastomotic healing and stability during advanced surgical procedures. These include a resorbable intraluminal stent graft and an extraluminal resorbable graft, along with anvil cap extension arms. By employing these products, SafeGuard aims to reduce surgical complications, lower healthcare costs, and minimize patient recovery time, ultimately preventing mortality and morbidity associated with surgery.
DasiSimulations
Non Equity Assistance in 2023
DasiSimulations is a company that specializes in providing innovative simulations aimed at enhancing pre-operative preparation for patients with heart disease, particularly those suffering from Structural Heart Disease. Founded in 2019 by Teri Anderson-Sirset and Dr. Dasi, and headquartered in Dublin, Ohio, DasiSimulations focuses on improving patient outcomes and reducing healthcare costs through advanced individualized computational predictive modeling. Utilizing artificial intelligence and proprietary algorithms, the company's technology platform empowers medical professionals to make more informed decisions during transcatheter aortic valve replacement procedures.
Senseye
Non Equity Assistance in 2023
Senseye, Inc. is a Los Angeles-based company founded in 2015 that specializes in developing innovative smart contact lenses capable of non-invasively recording and analyzing information from users. These contact lenses are designed to infer human emotions, thoughts, and health states, thereby assisting in various applications such as market research, disease diagnosis, and early detection of medical conditions like strokes and heart attacks. By utilizing novel measurements of ocular physiology, Senseye aims to quantify cognitive abilities and psychological well-being, providing valuable insights into vital signs, attention, cognitive load, and fatigue. The company is committed to advancing technology that enhances emotional responses and mental health diagnostics, enabling clinicians to offer personalized care and effectively track patient outcomes over time.
Xcision Medical Systems
Non Equity Assistance in 2023
Xcision Medical Systems develops advanced stereotactic radiotherapy solutions for treating breast cancer. Its radiosurgery device delivers gamma irradiation, enabling a single, non-invasive treatment session instead of weeks-long courses, reducing radiation exposure to surrounding tissues and allowing patients to resume normal lives more quickly.
Sonavi Labs
Non Equity Assistance in 2023
Founded in 2017 and headquartered in Baltimore, Maryland, Sonavi Labs is a medical technology company that develops innovative devices and software. It specializes in analyzing body sounds for disease diagnosis, utilizing artificial intelligence to enhance healthcare provider capabilities.
Ankr Health
Non Equity Assistance in 2023
Ankr Health uses AI and telemedicine to automate side effect management in cancer and surgical clinics. Founded in 2022 and is based in San Francisco, CA.
EchoPixel
Non Equity Assistance in 2023
EchoPixel develops advanced medical visualization software. Its flagship product, True 3D Viewer, enables real-time interactive exploration of patient-specific organs and tissues in a virtual reality environment, assisting doctors in identification, evaluation, and dissection of structures. The company also offers educational tools for medical students and intraoperative imaging support for structural heart procedures.
3EO Health
Non Equity Assistance in 2023
3EO Health is dedicated to creating a society where individuals are empowered to enhance their health across various aspects of life, including patient care, community engagement, and personal well-being. The company develops innovative molecular point-of-care platforms that utilize advanced technology to significantly reduce costs while improving access to impactful diagnostic tools. By leveraging its proprietary 3TR technology, 3EO Health offers molecular performance that is more affordable than existing options, ensuring equitable access to high-quality health solutions for both physicians and consumers. Its mission extends beyond traditional healthcare settings, aiming to integrate health optimization into communities, workplaces, and homes, thus fostering an environment where individuals can thrive.
CORIT Medical
Non Equity Assistance in 2023
CORIT Medical is a medical device company based in McLean, VA. It specializes in a Class I single-use surgical device designed to improve breathing during inferior turbinate reduction procedures. The device, which requires no expensive equipment, offers more durable results compared to competing technologies and enables ENTs to perform the procedure in their office, yielding higher reimbursement.
4th Dimension EMR
Non Equity Assistance in 2023
A software company specializing in healthcare solutions. It offers practice management and electronic medical record (EMR) systems designed to facilitate patient information administration and documentation for healthcare practitioners.
Thermidas
Non Equity Assistance in 2023
Thermidas, a Finnish health technology company, specializes in developing and advancing infrared thermal imaging for diagnostic purposes. Its core product is thermal imaging software, designed to support screening, early diagnostics, and evaluation of treatment effectiveness. The technology enables swift and simple detection of asymmetric body temperature, which can indicate underlying health issues like inflammation, circulatory problems, and potential ulcers. This allows university hospitals and experienced clinicians to identify and diagnose conditions at earlier stages than traditional methods.
Opticyte
Non Equity Assistance in 2023
Opticyte, Inc. is a medical device company based in Seattle, Washington, specializing in the development of advanced algorithms and optical spectroscopy technology to monitor cellular oxygen levels. Founded in 2016 as a spinoff from the University of Washington, the company is focused on creating its first product, the Cell O2 Monitor, which aims to reduce the risk of organ failure. This innovative noninvasive oximeter measures oxygen levels within cells, enabling early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By providing clinicians with essential data, Opticyte's technology facilitates timely treatment decisions that can prevent multiple organ failure and improve patient outcomes. The company comprises teams with extensive experience in engineering, regulatory affairs, and communications, all dedicated to advancing medical device innovation.
Neurava
Non Equity Assistance in 2023
Neurava is a healthcare company focused on improving the lives of epilepsy patients through the development of non-invasive wearable diagnostic devices. These devices monitor critical biological signals associated with epilepsy and the risk of sudden unexpected death in epilepsy (SUDEP), offering a reliable solution for both patients and their caregivers. By providing accurate and timely alerts, especially during nighttime, Neurava's technology empowers caregivers to respond quickly and take preventive actions, thereby enhancing patient safety and peace of mind. The company's commitment to advancing medical device manufacturing and health diagnostics highlights its role in addressing the challenges faced by those with uncontrolled epilepsy.
Covellus
Non Equity Assistance in 2023
Covellus is a medical device company focused on developing innovative platform technology for catheters used in minimally invasive surgeries. The company specializes in manufacturing vascular catheter devices and modular catheter systems, which allow physicians to customize existing devices to meet the specific needs of individual patients. By enhancing the versatility and adaptability of medical devices, Covellus aims to improve treatment outcomes in various medical procedures.
Prana Thoracic
Non Equity Assistance in 2023
Prana Thoracic, Inc., based in Houston, is a medical device startup focused on developing innovative solutions for the early intervention of lung cancer, the leading cause of cancer-related deaths in the United States. The company aims to address the critical challenges in lung cancer screening and diagnosis, where only a small percentage of cases are detected at an early stage. Prana Thoracic's advanced electrosurgical instrument utilizes bipolar radiofrequency energy to perform minimally invasive procedures, enabling physicians to capture and diagnose small, hard-to-reach lung nodules while reducing the risk of complications. By enhancing the tools available for surgical oncology in lung cancer, Prana Thoracic seeks to improve patient outcomes and capitalize on recent advancements in screening guidelines, ensuring early intervention opportunities are not missed.
Sparta Biomedical
Non Equity Assistance in 2023
Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.
Alyve Medical
Non Equity Assistance in 2023
Alyve Medical designs and manufactures medical devices that incorporate sensors for therapeutic and diagnostic use, focusing on musculoskeletal conditions. Its neuromuscular electrical stimulation (NMES) products stimulate neuroplasticity to enhance recovery, while its physical therapy and rehabilitation devices help patients regain and improve range of motion and function.
HIVE Medical
Non Equity Assistance in 2023
Healthcare is moving to the outpatient setting to save costs, but at home patients struggle with medication adherence and they are readmitted at alarming rates. Hospitals send 1.4 million patients home for 4-6 weeks to administer their own IV antibiotics every year. Twenty percent of patients on outpatient parenteral antimicrobial therapy (OPAT) are readmitted, each costing $80,000 on average. This is a $22.4 billion problem. Clinicians at the 12,200 home infusion providers in the US have no objective way to identify non-adherence to intervene and prevent readmissions. Rather, they call patients to detect non-adherence, which is time-consuming, inaccurate, and prone to reporting bias. They need a better tool than a phone to monitor adherence.
The solution is HIVE’s patent pending CloudConnect smart catheter. CloudConnect is a reinvented IV line with a simple embedded mechanoelectrical sensor that detects when a medication source is connected. CloudConnect wirelessly sends this information to electronic medical records. HIVE’s value proposition is that clinicians can detect non-adherence in real time and make treatment decisions and prevent costly readmissions based on objective data. HIVE offers CloudConnect as an alternative to the need for clinicians to call every patient with standard IV lines.
LiveMetric
Non Equity Assistance in 2022
LiveMetric is a medical device company focused on developing innovative, non-invasive sensing and deep data analytics solutions aimed at improving the management of hypertension and cardiovascular diseases. The company offers a wearable, cuff-free device for blood pressure monitoring that is FDA-cleared and validated for accuracy against traditional arterial line methods. This technology provides high-fidelity arterial pressure waveforms and continuous tracking of vital signs, allowing for real-time feedback and analysis for patients, physicians, and healthcare providers. By delivering personalized data and detailed activity mapping, LiveMetric aims to empower individuals, payors, self-insured employers, and healthcare providers, ultimately enhancing the care and quality of life for over one billion people worldwide affected by these conditions.
CARI Health
Non Equity Assistance in 2022
CARI Health develops wearable remote medication monitors that attach to the skin and continuously transmit data about medication levels to the cloud, enabling clinicians to prescribe medications and monitor real-time exposure. The sensor-enabled system supports personalized dosing by facilitating safe titration of therapies with narrow therapeutic windows, potentially improving dosing precision and patient outcomes. The company was founded in 2015 and is based in San Diego, California.
Garwood Medical Devices
Non Equity Assistance in 2022
Garwood Medical Devices, LLC is a Buffalo, New York-based company that develops and manufactures innovative medical devices aimed at combating infections related to prosthetic implants and wound healing. The company specializes in BioPrax, a minimally invasive device designed to target and eliminate biofilm infections on prosthetic knee implants during early intervention procedures. By effectively addressing infection-causing bacteria without necessitating follow-up surgeries, Garwood Medical Devices enables healthcare practitioners to improve treatment outcomes and help patients retain their implants. Originally founded as Enermed, LLC in 2014, the company rebranded to its current name in December 2015, reflecting its commitment to advancing medical technology in the field of infection management.
CardiaCare
Non Equity Assistance in 2022
CardiaCare is a developer of a wearable medical device aimed at the non-invasive treatment and monitoring of atrial fibrillation (AFib) in patients. The company's innovative device employs a closed-loop approach combined with machine learning algorithms to deliver personalized peripheral neuromodulation. This technology mediates a cardiovascular antiarrhythmic response, enabling users to effectively reduce the burden of atrial fibrillation and its precursors, such as premature atrial contractions. As a result, CardiaCare’s solution offers users rapid clinical and symptomatic relief, providing a valuable tool for managing their condition in a home setting.
52 North
Non Equity Assistance in 2022
52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.
SafeBeat Rx
Non Equity Assistance in 2022
SafeBeat Rx is a technology company specializing in advanced electrocardiogram solutions aimed at enhancing cardiac care. The company has developed software that facilitates remote patient monitoring, continuous telemetry, and event monitoring, significantly reducing the need for prolonged hospital stays for cardiac patients. By leveraging automated artificial intelligence, SafeBeat Rx's technology allows for safe medication initiation for arrhythmia patients while enabling effective monitoring of cardiac implantable electronic devices. This innovative approach expands access to cardiac care, allowing patients to receive essential services from the comfort of their homes.
Augment Health
Non Equity Assistance in 2022
Augment Health is a company focused on developing noninvasive medical devices and artificial intelligence algorithms to enhance the management of bladder dysfunction, particularly for the 7 million patients affected by neurologic disease or injury. The company's innovative technology allows for monitoring urine levels through a device that can be attached to catheters, providing timely notifications to users or care providers when the catheter reaches capacity. This approach aims to shift bladder diagnostics from clinical settings to patients' homes, addressing the high rate of inconclusive test results associated with traditional in-clinic diagnostics. By enabling better bladder health management, Augment Health seeks to prevent complications such as bladder muscle atrophy, ultimately improving the quality of life for patients.
SymPhysis Medical
Non Equity Assistance in 2022
SymPhysis Medical is focused on developing innovative medical technologies aimed at treating chronic diseases, with a particular emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, is a therapeutic device designed for the home management of malignant pleural effusions (MPE), a common complication in late-stage cancer patients. MPE can lead to severe symptoms such as shortness of breath and chest pain, affecting approximately 15% of cancer patients. The releaze device effectively drains excess fluid from the pleural space, utilizing an active component to improve removal efficiency. This technology not only alleviates debilitating symptoms but also makes indwelling pleural catheter treatments more accessible for patients, significantly contributing to their overall well-being.
DermaSensor
Non Equity Assistance in 2022
DermaSensor develops a handheld device that uses artificial intelligence to evaluate skin lesions for signs of cancer. Its primary product, DermaSensor, enables physicians and consumers to perform skin checks in offices and homes, potentially saving lives and healthcare costs by increasing accessibility to effective skin cancer evaluation.
ConKay Medical Systems
Non Equity Assistance in 2022
ConKay Medical Systems is an early-stage medical device company focused on creating innovative solutions for treating valvular regurgitation in patients experiencing progressive heart failure. The company has developed a device that utilizes annular repair technology to address the primary cause of functional regurgitation, preserving the integrity of healthy leaflets to ensure they function as intended. By advancing cardiovascular care, ConKay Medical Systems aims to improve treatment outcomes for patients with this serious condition.
Endoron Medical
Non Equity Assistance in 2022
Endoron Medical is a company focused on developing innovative medical devices aimed at enhancing the treatment of abdominal aortic aneurysms. The company specializes in creating an endovascular suture and a fixation device for endografts, which are essential for patients undergoing endovascular aneurysm repair. By employing advanced technology, Endoron Medical aims to provide long-lasting sealing solutions that improve patient outcomes and support healthcare professionals in effectively managing this serious condition.
CloudMedx
Non Equity Assistance in 2022
CloudMedx Inc. is a software development company that specializes in artificial intelligence solutions aimed at extracting critical clinical insights from electronic health records. Founded in 2014 and based in Palo Alto, California, the company transforms raw healthcare data into actionable insights that enhance clinical operations, documentation, and patient care. Its platform leverages population health history to improve clinical, treatment, and diagnostic outcomes, while also notifying physicians when care is necessary. CloudMedx provides patient-centric tools that facilitate engagement, risk stratification, and actionable insights, serving a range of healthcare entities including managed care organizations, accountable care organizations, physician-led organizations, emergency rooms, urgent care facilities, and lab testing sites. The company’s mission is to unify healthcare systems, enabling better collaboration among providers, payers, and patients, ultimately improving the accuracy and quality of care delivered.
Corveus Medical
Non Equity Assistance in 2022
Corveus Medical is a medical device company focused on innovative solutions for preventing heart failure. The company is developing a neuromodulation device designed to perform nerve ablation through a catheter-based approach. This minimally invasive technology aims to effectively target and access specific tissues, offering a novel treatment option for heart failure. By addressing both the clinical and economic challenges associated with this condition, Corveus Medical seeks to improve patient outcomes and enhance the overall management of heart failure.
Phagenesis
Non Equity Assistance in 2022
Phagenesis develops a medical device for treating dysphagia, a swallowing disorder often resulting from stroke or brain injury. The device, Phagenyx, uses neurostimulation therapy to harness the brain's capacity for relearning lost functions via neuroplasticity. It consists of a base station and a catheter inserted through the nose, delivering optimal stimulations to the pharynx while recording patient data.
Tricog Health
Non Equity Assistance in 2022
Tricog Health is a company that specializes in cardiac diagnostic tools aimed at addressing cardiovascular conditions through real-time identification and accurate analysis. Utilizing medical-grade artificial intelligence, Tricog improves cardiac care by bridging gaps in infrastructure, expertise, and efficiency within healthcare systems. The company offers virtual diagnostic tools and services that empower healthcare providers to make timely and precise diagnoses, ultimately enhancing patient outcomes. Tricog's innovative medical device facilitates real-time reporting and analysis of electrocardiography results without the need for additional hardware, ensuring early detection of potentially life-threatening cardiac events.
Digma Medical
Non Equity Assistance in 2022
Digma Medical is a clinical stage medical device company focused on innovative treatments for Type-2 Diabetes and related metabolic disorders, including NASH. Founded in 2013, the company is developing the DiaGone™, a disposable endoscopic device that employs advanced laser technology to target the duodenum, the first section of the small intestine. This device is designed to address insulin resistance, the core issue in these diseases. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to utilize the DiaGone™ to enhance the body's natural ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and improve overall health outcomes.
Healthcare X.0 - HealthAssist
Non Equity Assistance in 2022
Healthcare X.0 is an online healthcare platform that provides its clients with digitization solutions.
The platform provides its clients with health, vascular, patient, onco, nephro, cardio, wound, tele, patient, and diabetic assist database solutions.
Healthcare X.0 was launched in 2013 by and is based in Niedersachsen.
PyrAmes
Seed Round in 2020
PyrAmes is a healthcare technology company that has created an innovative, paper-thin, flexible device for non-invasive blood pressure monitoring. This ultra low-power device is designed to deliver continuous and accurate blood pressure measurements wirelessly, making it suitable for patients of all ages, from newborns to seniors. PyrAmes aims to transform healthcare delivery by providing a platform that enables healthcare providers to conduct pain-free blood pressure monitoring, particularly benefiting vulnerable populations such as neonates.
HD Medical
Seed Round in 2019
HD Medical develops a visual stethoscope integrated with an electrocardiogram for real-time detection of cardiac anomalies at the point of care. The device displays heart waveforms, records results, and aids healthcare professionals in early cardiovascular disease diagnosis and management.
Sepsis Scout
Seed Round in 2019
Sepsis Scout is a developer of a wearable patch designed to predict the onset of sepsis in high-risk patients in home care settings. Utilizing proprietary deep learning technology, the device aims to detect sepsis more accurately than current standards of care. By enabling patients to manage chronic illnesses effectively, Sepsis Scout's solution helps individuals stay out of the hospital and alleviates the fear and uncertainty associated with serious health conditions. The company's focus on artificial intelligence and wearables positions it at the forefront of innovative healthcare solutions.
Avisi Technologies
Seed Round in 2019
Avisi Technologies Inc. is a Philadelphia-based company founded in 2017 that specializes in developing innovative solutions for glaucoma treatment. Its primary product, VisiPlate, is a next-generation, nanotechnology-enabled aqueous shunt designed to prevent blindness caused by glaucoma. Through its advanced technology, Avisi Technologies aims to enhance the effectiveness of glaucoma management and improve patient outcomes.
Subtle Medical
Seed Round in 2019
Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.
ZKR Orthopedics
Seed Round in 2019
ZKR Orthopedics is focused on developing innovative medical devices and procedures to treat chronic knee pain, particularly caused by Condromalacia Patellae, a condition characterized by the degeneration of cartilage and inflammation beneath the kneecap. Millions of individuals suffer from this ailment, often delaying medical treatment due to the traditionally invasive nature of available solutions, which typically involve major surgery. ZKR's approach offers a minimally invasive option that aims to alleviate pain, restore mobility, and potentially reduce the need for knee replacement surgery. The company, founded by Dr. Jeffrey Halbrecht, has successfully developed prototypes and holds multiple patents for its technology. Currently, ZKR is seeking capital to fund product trials, further advancing its mission to improve patient outcomes in orthopedic care.
Respirix
Seed Round in 2019
Respirix, Inc. is a United States-based company focused on developing advanced analysis sensors for monitoring breath exhalation and cardiogenic oscillations. The company offers digital health software and hardware designed to provide proprietary insights into the pulmonary vasculature in a non-invasive manner. Respirix's product pipeline targets both at-home monitoring and critical care applications, specifically in areas such as heart failure and hemodynamics. Its innovative approach aims to enhance patient care by delivering precise and actionable data related to respiratory and cardiovascular health.
InVera Medical
Seed Round in 2019
InVera Medical specializes in developing innovative medical devices focused on treating chronic venous disease. Their flagship product, BioVena™, offers a less invasive, pain-free solution for varicose veins and venous ulcers, utilizing the body's natural biological response.
CloudCath
Seed Round in 2019
CloudCath is a company that specializes in developing a sensor-enabled digital platform tailored for patients undergoing peritoneal dialysis. The platform integrates Internet of Things-based sensing hardware with a continuous monitoring system, allowing for the early detection of complications associated with catheter-based treatments. This innovative approach not only enhances patient care by enabling healthcare providers to monitor patients remotely during their home treatments but also aims to reduce the frequency of in-person visits required each month. By focusing on early complication detection, CloudCath seeks to improve patient outcomes in the management of dialysis therapy.
AMT Surgical
Grant in 2019
AMB Surgical is a developer of innovative medical devices aimed at treating pediatric deformities, particularly scoliosis. The company has created an electro-mechanical smart automated growing rod known as "FLYTE," which allows for precise and frequent non-surgical adjustments through sensor feedback. This technology enhances the capabilities of surgeons in managing complex cases involving pediatric scoliosis, dynamic external fixation for deformity correction, and applications related to long bone lengthening. By providing a solution that minimizes the need for invasive surgical procedures, AMB Surgical aims to improve treatment outcomes for children facing these conditions.
Conavi Medical
Seed Round in 2018
Conavi Medical develops catheter-based imaging technologies to guide minimally invasive cardiovascular procedures. Its ultrasound system provides 2-D and 3-D images around the catheter tip, enabling clinicians to visualize cardiac anatomy during procedures such as ablations. The Novasight Hybrid System combines intravascular ultrasound and optical coherence tomography to provide simultaneous, co-registered imaging of coronary arteries, improving visualization during interventions.
Impleo Medical
Seed Round in 2018
Impleo Medical is a company focused on developing minimally invasive medical devices specifically for the treatment of gastroesophageal reflux disease (GERD). It has created an outpatient injection therapy platform that allows for a one-time procedure under sedation, providing durable relief from acid reflux. This innovative approach addresses a significant gap in treatment options, lying between traditional medications and surgical interventions. By enabling physicians to effectively prevent the flow of gastric acid into the esophagus, Impleo Medical aims to enhance patient outcomes and improve quality of life for those suffering from GERD.
Spire Health
Seed Round in 2018
Spire Health, established in 2013 and headquartered in San Francisco, specializes in developing health-tracking devices and remote patient monitoring solutions. The company's core product is a wearable device that senses physical movement, position, and breathing patterns, providing insights into daily activities and mental state through a mobile application. Spire Health focuses on chronic respiratory disease management, offering solutions for conditions such as COPD, congestive heart failure, asthma, and sleep disorders. Their mission is to empower patients and physicians with useful, actionable data by harnessing the power of algorithms and sensors, thereby improving health outcomes.
ODS Medical
Seed Round in 2018
ODS Medical Inc. is a Montreal-based medical device company established in 2015, specializing in the design and manufacture of advanced diagnostic tools for cancer detection. The company's flagship product is an exclusive Raman spectroscopy system that enables real-time identification of tissue abnormalities across various clinical settings. By integrating innovative optical probes with sophisticated software powered by machine learning algorithms, ODS Medical aims to enhance the capabilities of physicians, allowing for critical decision-making with high sensitivity, specificity, and accuracy. Through its commitment to developing and commercializing cutting-edge technology, ODS Medical strives to revolutionize the diagnostic landscape in oncology.
PhotoniCare
Seed Round in 2018
PhotoniCare is a medical device company that develops ear-diagnosis devices using light-based technology to see through the eardrum into the middle ear, enabling clinicians to visualize the contents and determine whether antibiotics or surgical interventions are needed. Its flagship device, TOMi Scope, uses near-infrared light to provide views beyond the eardrum and support assessment through optical coherence imaging. The company's imaging platform aims to extend its applications beyond otology and improve clinical decision-making in middle-ear infections. PhotoniCare was founded in 2013 and is based in Champaign, Illinois.
CU-BX is a health analytics platform focused on enhancing driver safety and comfort through advanced monitoring solutions. The company specializes in providing high-accuracy measurements of various health parameters, including fatigue, stress, heart rate, and respiratory rate. Its patented technology ensures reliable performance across diverse road and lighting conditions and is adaptable to various clothing and accessories. CU-BX collaborates with major automotive stakeholders, including original equipment manufacturers and suppliers, to develop driver monitoring systems and aftermarket solutions. By integrating sophisticated sensors and dashcam data, CU-BX aims to improve in-cabin comfort and promote safer driving practices, making it a key player in the automotive health analytics sector.
Darmiyan
Seed Round in 2018
Darmiyan develops a SaaS platform, BrainSee, for early detection and monitoring of neurodegenerative diseases like Alzheimer's. Using standard MRI scans and cognitive tests, BrainSee generates detailed brain maps and scores indicating neurodegeneration, enabling timely diagnosis and intervention.
Deton is a diagnostics company focused on lung health. It develops technology to improve understanding and treatment of lung disease by providing timely lung health information through Aerosol Biopsy. Its platform aims to detect lower respiratory tract infections by obtaining samples from the lower airways and analyzing bacterial elements to study microbial growth over time, enabling clinicians to diagnose infections and guide treatment decisions for lung disorders.
Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.
Day Zero Diagnostics
Grant in 2017
Day Zero Diagnostics develops sequencing-based diagnostics for infectious diseases. Its proprietary technologies enable rapid identification of bacterial species and antibiotic resistance profiles from clinical samples, targeting bloodstream infections and sepsis initially. The company aims to improve patient outcomes by providing comprehensive diagnoses within hours instead of days.
PharmaJet
Series F in 2017
PharmaJet develops and markets needle-free jet injectors for vaccine delivery, enabling administration without a needle and reducing sharps injuries, needle reuse, cross-contamination, and medical waste. Its Stratis and Tropis platforms are designed to deliver vaccines intramuscular, subcutaneous, or intradermal across various volumes, offering a potential return on investment by lowering risk and waste. Founded in 2005 and based in Golden, Colorado, PharmaJet focuses on delivering safe, user-friendly devices that support immunization programs and aim to simplify injections while expanding access to vaccination.
Otricath is a medical technology company focused on improving the delivery of cancer therapies, particularly for liver cancer. The company has developed a closed-loop catheter system that allows healthcare professionals to administer chemotherapy directly to solid tumors while minimizing systemic toxicity. This innovative platform features a three-part catheter designed to deliver anticancer agents in a sealed environment, ensuring enhanced control, predictability, and safety in treatment. By concentrating treatment directly at the tumor site, Otricath aims to optimize therapeutic benefits for patients undergoing cancer treatment.
Innoblative Designs
Venture Round in 2017
Innoblative Designs, Inc. is a medical device company based in Chicago, Illinois, with an additional office in Mansfield, Massachusetts. Established in 2013, the company specializes in the development of innovative electrosurgical devices aimed at enhancing surgical procedures. One of its key products is Sira™, a Saline-assisted Intraoperative Radiofrequency Ablation device. This device utilizes bipolar current to create a controlled zone of ablation during surgery, facilitating the coagulation and ablation of soft tissue beds. Sira's unique design features a saline microinfusion system that ensures optimal contact with target tissue, allowing it to be seamlessly integrated with existing electrosurgical generators in operating rooms. This makes Sira an accessible and effective option for surgeons seeking to improve intraoperative ablation techniques.
Patientory Inc., established in 2015 and headquartered in Atlanta, Georgia, specializes in developing a personal healthcare solution named Patientory. This platform enables individuals to securely manage their medical records, monitor chronic illnesses, and access relevant health information. Simultaneously, it facilitates healthcare providers' connection with patients for support and care coordination. By empowering users to control their health data and incentivizing healthier lifestyles through personalized rewards, Patientory aims to streamline interactions between healthcare stakeholders and patients while reducing care costs.
Access Vascular
Grant in 2017
Access Vascular, Inc. is a medical technology company based in Bedford, Massachusetts, founded in 2015. The company specializes in developing innovative venous access devices that utilize advanced hydrogel materials to significantly reduce thrombosis accumulation, a common complication in intravenous therapy. Their product line includes peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. By addressing critical issues such as occlusions and infections, Access Vascular aims to enhance clinical outcomes, lower healthcare costs, and improve patient experiences. The company's HydroPICC catheter exemplifies their commitment to advancing venous access technology, as it offers superior performance over existing solutions, thereby increasing catheter dwell time and minimizing associated complications.
M&S Biotics develops healthcare IoT systems that enhance surgical efficiency, safety, and outcomes by automating instrument counting and data collection in the operating room. Its Biotic Integration system uses radio frequency identification and artificial intelligence to track, count, and locate surgical items in real time, while Biotic Insight provides analytics on instrument utilization. The platform also includes a Smart Table for real-time monitoring and coordination of tools and staff across procedures, enabling hospitals to reduce procedural risks, optimize resource use, and potentially increase surgical capacity.
NovaGray is a biotechnology company focused on the development of advanced companion diagnostic tests designed to enhance radiation therapy planning. The company’s innovative biomarker-based tests evaluate patient sensitivity through a single blood sample, allowing healthcare practitioners to customize treatment doses and session sequences based on individual patient profiles. This personalized approach aims to improve patient outcomes while simultaneously reducing complications and overall treatment costs. By enabling physicians to tailor standard radiotherapy treatments to the specific sensitivities of patients, NovaGray seeks to significantly advance the efficacy of cancer care.
VADovations, Inc. is an Oklahoma City-based company focused on designing and manufacturing innovative healthcare equipment, particularly in the field of cardiac assistance. Founded in 2009, VADovations specializes in developing a miniature ventricular assist device, a mechanical blood pump that is smaller and lighter than existing options. This advanced device allows for less invasive surgical implantation, significantly reducing hospitalization time from three weeks to just four days. The technology is designed to provide circulatory support for patients with end-stage heart failure, utilizing percutaneous delivery and endovascular deployment methods. By minimizing the risks associated with traditional blood pumps, such as stroke, bleeding, thrombosis, and infection, VADovations aims to enhance the safety and effectiveness of cardiac procedures performed by cardiothoracic surgeons and interventional cardiologists.
2Morrow is a digital health company that develops, licenses, and distributes evidence-based behavioral change programs and digital health products. Its programs include SmartQuit, an evidence-based smoking cessation program using acceptance commitment therapy; My Pocket Coach, a personal goal and habit platform; and Healthy Habits to establish or break routines. Delivered through employers, state programs, wellness initiatives, and health plans, the offerings support population health and well-being. The company emphasizes behavioral science and data-driven tools, with more than a dozen published studies and a Phase III randomized controlled trial in digital health. Based in Kirkland, Washington, 2Morrow has an active product pipeline extending into substance-use support and management of chronic conditions, helping individuals align behavior with personal values to sustain lasting change.
Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.
VerteCore is a developer of an innovative orthopedic medical device aimed at relieving lower back pain. The company has created the VerteCore Lift, a patent-pending system that offers a non-surgical approach to spinal decompression. This device targets various sources of back pain, including compressed or bulging discs, sciatica, and functional scoliosis, using a dual support harness and a unique ratcheting mechanism for ease of use. By providing a convenient and mobile solution, VerteCore enables active individuals to find rapid relief from spinal discomfort without the need for hospitalization, medication, or surgical intervention.
Abreos Biosciences
Grant in 2017
Abreos Biosciences develops lateral flow assays that quantify the activity of biologic drugs. Its peptide‑based detection reagents enable rapid assessment of monoclonal antibody concentrations from whole blood, supporting precision dosing and pharmacokinetic monitoring. The company also offers ligand‑binding assays for biologic and biosimilar development, authentication, and activity validation, as well as massively multiplexed biomarker panels. Its C3‑LFA platform is used for authenticating biologics such as BOTOX and for endotoxin testing in medical devices, pharmaceuticals, research, biodefense, and food safety. Additionally, the MudPAQ sensor platform converts proteomic data into genetic codes for multiplexed protein detection, aiding cancer biomarker studies and host response analysis. Founded in 2013, the company is headquartered in San Diego, California, with a laboratory in San Diego and an office in Marseille, France.
Nanowear, Inc. is a technology company specializing in textile-based nanosensor solutions for wireless and real-time electrophysiological monitoring. Founded in 2014 and headquartered in Brooklyn, New York, with a research and development facility in University Park, Pennsylvania, Nanowear develops innovative products such as SimplECG, a remote cardiac monitoring undergarment, and SimpleSense, designed for the management of congestive heart failure. These garments collect multi-channel electrocardiogram (ECG), heart rate, and respiratory rate data, transmitting it to a web-based portal accessible by healthcare professionals via a mobile application. The company's proprietary technology serves various markets, including cardiac, neurological, industrial safety, government, sports medicine, and performance diagnostics, providing accurate, continuous, and cost-effective diagnostic data in an unobtrusive manner.
Centerline Biomedical
Grant in 2017
Centerline Biomedical, Inc. is a Cleveland, Ohio-based company founded in 2014 that specializes in developing advanced surgical navigation technologies. The company focuses on an Intra-Operative Positioning System, which utilizes non-x-ray based three-dimensional GPS technology to enhance the precision of endovascular procedures and minimize radiation exposure for both patients and medical staff. Centerline's innovative system aids surgeons in navigating complex three-dimensional vascular anatomy, thereby improving surgical outcomes in interventional vascular procedures. The technology is rooted in advancements made at the Cleveland Clinic, reflecting a commitment to enhancing the safety and effectiveness of minimally invasive surgeries.
Eyetronic Therapie
Grant in 2017
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.
PneuMotion is a manufacturer of advanced respiratory monitoring equipment focused on detecting opioid-induced ventilation impairment. The company specializes in continuous respiratory rate monitoring and obstructive apnea detection, providing healthcare facilities with an effective means to enhance patient safety, particularly in opioid administration contexts. PneuMotion's technology is designed for seamless integration into existing hospital networks, facilitating mobile respiratory monitoring and electronic health record (EHR) data collection. By utilizing ultra-low cost sensor technology, PneuMotion offers a cost-effective solution for improving patient outcomes and ensuring safety in clinical settings.